Sarah Rutherford, MD, Weill Cornell Medical College

Articles by Sarah Rutherford, MD, Weill Cornell Medical College

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Latest Updated Articles

$ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas$
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
January 22nd 2021
ASH 2020 Updates in CLL
January 22nd 2021
ASH 2020 Updates in Non-CLL B-Cell Lymphomas
January 22nd 2021

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

Dr Pelster on the Rationale for Investigating Atebimetinib in Metastatic Pancreatic Cancer

Peak Sets the Stage for Bezuclastinib/Sunitinib to Move Into the Advanced GIST Treatment Paradigm

China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC